Jiang Lin, PhD

Moderna, Inc.
Cambridge, Massachusetts, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 2892 - Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial

  Saturday, October 14, 2023
  2:25 PM – 2:35 PM US ET